

Multistep Synthesis of Cationic Lipid-like Compounds Based on a Difluorotetrahydropyridine Scaffold as Amphiphilic Nanocarriers

Martins Kaukulis,^a Martins Rucins,^a Ruslans Muhamadejevs,^a Anatoly Mishnev,^a Karlis Pajuste,^a Aiva Plotniece,^{a,b} Arkadij Sobolev,^a and Nadiia Pikun ^{*a}


TABLE OF CONTENT

Synthesis of 1,4-Dihydropyridines 1h-j and 1m	2
Monofluorination of 1,4-dihydropyridines 1a,e	3
Heck reaction.....	4
Bromination of compound 2d	5
Optimisation of quaternisation reaction	5
Dynamic light scattering measurements.....	6
NMR spectra of 1,4-dihydropyridines 1h-j and 1m	6
NMR spectra of monofluorinated compounds 1'a and 1'e	11
NMR spectra of pyridines Ox-1'a and Ox-1'e	15
NMR spectra of difluorinated compounds 2a-o	17
NMR spectra of halogenated 2-methyltetrahydropyridines 7a-c	37
¹ H-NMR spectrum of bromination intermediate 10	41
NMR spectra of compound 13a-c obtained in Pd-catalysed reactions	42
NMR spectra of pyridinium moiety containing compounds 14a-c and 15a-c	46
Crystallization procedure, crystal data, data collection and structure refinement details	55

^a Latvian Institute of Organic Synthesis, Aizkraukles Str. 21, Riga LV-1006.

^b Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Riga Stradiņš University, Konsula 21, LV-1007, Riga, Latvia.

1.1. Synthesis of 1,4-dihydropyridines 1h-j,m.



Scheme S1. Synthesis of 1,4-dihydropyridines **1h,i,m**.

Didodecyl 2',6'-dimethyl-1',4'-dihydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**1h**).

A mixture of dodecyl 3-oxobutanoate (2.5 g, 9.5 mmol), 3-pyridinecarboxaldehyde (0.5 g, 439 μL , 4.73 mmol) and ammonium acetate (0.51 g, 7.1 mmol) was stirred at reflux in ethanol (15 mL) for 8 h. After cooling the reaction mixture to 4 °C, the resulting precipitates were filtered, recrystallised from ethanol, and dried under vacuum giving compound **1h** (1.65 g, 58%) as a slightly yellow solid; Mp. 144–145 °C, decomposition. $^1\text{H-NMR}$ (400 Hz, CDCl_3): δ 8.52 (dd, $^3J_{\text{H-H}} = 2.4$ Hz, $^4J_{\text{H-H}} = 0.8$ Hz, 1H, CH, Py), 8.36 (dd, $^3J_{\text{H-H}} = 4.8$ Hz, $^4J_{\text{H-H}} = 1.7$ Hz, 1H, CH, Py), 7.61 – 7.54 (m, 1H, CH, Py), 7.13 (ddd, $^3J_{\text{H-H}} = 7.8$ Hz, $^3J_{\text{H-H}} = 4.8$ Hz, $^4J_{\text{H-H}} = 0.9$ Hz, 1H, CH, Py), 6.06 (s, 1H, NH), 4.98 (s, 1H, CH(4)), 4.09 – 3.95 (m, 4H, $2 \times \text{COOCH}_2(\text{CH}_2)_{10}\text{CH}_3$), 2.34 (s, 6H, $2 \times \text{CH}_3$), 1.63 – 1.54 (m, 4H, $2 \times \text{COOCH}_2(\text{CH}_2)_9\text{CH}_2\text{CH}_3$), 1.30 – 1.23 (m, 36H, $2 \times \text{COOCH}_2(\text{CH}_2)_9\text{CH}_2\text{CH}_3$), 0.92 – 0.82 (m, 6H, $2 \times \text{COOC}_{11}\text{H}_{22}\text{CH}_3$) ppm. $^{13}\text{C-NMR}$ (101 Hz, CDCl_3): δ 167.4, 149.7, 147.4, 144.8, 143.4, 135.7, 123.2, 103.5, 64.3, 37.9, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 28.8, 26.2, 22.8, 19.7, 14.3 ppm. HRMS (TOF MS ES⁺): calculated [$\text{C}_{38}\text{H}_{63}\text{N}_2\text{O}_4 + \text{H}$] 611.4788; found 611.4796.


Didodecyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-pyridine-3,5-dicarboxylate (**1i**).

A mixture of dodecyl 3-oxobutanoate (2.05 g, 7.6 mmol), 3-nitrobenzaldehyde (0.56 g, 3.7 mmol) and ammonium acetate (0.43 g, 5.6 mmol) was stirred at reflux in ethanol (15 mL) for 24 h. After cooling the reaction mixture to 4 °C, the resulting precipitates were filtered, washed with cold methanol, and dried under vacuum giving compound **1i** (1.4 g, 77%) as a yellow solid; Mp. 88–89 °C. $^1\text{H-NMR}$ (400 Hz, CDCl_3): δ 8.15 – 8.09 (m, 1H, CH, Ph), 8.05 – 7.96 (m, 1H, CH, Ph), 7.68 – 7.59 (m, 1H, CH, Ph), 7.40 – 7.31 (m, 1H, CH, Ph), 5.72 (s, 1H, NH), 5.09 (s, 1H, CH(4)), 4.10 – 3.95 (m, 4H, $2 \times \text{COOCH}_2(\text{CH}_2)_{10}\text{CH}_3$), 2.37 (s, 6H, $2 \times \text{CH}_3$), 1.63 – 1.53 (m, 4H, $2 \times \text{COOCH}_2(\text{CH}_2)_9\text{CH}_2\text{CH}_3$), 1.30 – 1.21 (m, 36H, $2 \times \text{COOCH}_2(\text{CH}_2)_9\text{CH}_2\text{CH}_3$), 0.91 – 0.84 (m, 6H, $2 \times \text{COOC}_{11}\text{H}_{22}\text{CH}_3$) ppm. $^{13}\text{C-NMR}$ (101 Hz, CDCl_3): δ 167.3, 150.0, 148.3, 144.8, 134.6, 128.7, 123.2, 121.5, 103.6, 64.4, 40.0, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 28.8, 26.2, 22.8, 19.8, 14.3 ppm. HRMS (TOF MS ES⁺): calculated [$\text{C}_{39}\text{H}_{61}\text{N}_2\text{O}_6 + \text{H}$] 653.4530; found 653.4532.

Bis(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononyl) 2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate (**1m**).

2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate (**1m**).


A mixture of 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluoro 3-oxobutanoate (2.5 g, 4.8 mmol), benzaldehyde (0.51 g, 480 μL , 2.4 mmol) and 25% ammonia solution (0.41 g, 456 μL , 3.6 mmol) was stirred at 100 °C in 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononan-1-ol (5 mL) for 24 h and then concentrated in vacuum. The crude product was purified by flash chromatography (eluent: EtOAc/Hexane 1:1) giving compound **1m** as a slightly yellow oil (1.32 g, 25%). $^1\text{H-NMR}$ (400 Hz, DMSO-d_6): δ 9.37 (s, 1H, NH), 7.34 – 7.01 (m, 7H, $5 \times \text{CH}$, Ph and $2 \times \text{COOCH}_2(\text{CF}_2)_8\text{H}$), 4.90 – 4.75 (m, 3H, CH(4) and $\text{COOCH}_2(\text{CF}_2)_8\text{H}$), 4.59 (q, $^3J_{\text{H-F}} = 13.6$ Hz, 2H, $\text{COOCH}_2(\text{CF}_2)_8\text{H}$), 2.31 (s, 6H, $2 \times \text{CH}_3$) ppm. $^{13}\text{C-NMR}$ (101 Hz, DMSO-d_6): δ 165.3, 148.9, 147.7, 128.5, 127.4, 126.8, 108.4, 101.1, 59.1, 58.9, 58.7 (t, $J = 26$ Hz), 58.6, 38.2, 18.7 ppm. $^{19}\text{F-NMR}$ (376 Hz, DMSO-d_6): δ -118.58 (s, 4F), -122.10 (s, 12F), -122.66 (d, $J = 15$ Hz, 4F), -123.22 (s, 4F), -129.01 (s, 4F), -138.61 (d, $J = 50$ Hz, 4F) ppm. HRMS (TOF MS ES⁺): calculated [$\text{C}_{33}\text{H}_{20}\text{NO}_4\text{F}_{32} + \text{H}$] 1102.0881; found 1102.0897.



Scheme S2. Synthesis of 1,4-dihydropyridine **1j**.

Didodecyl 4-ethyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (1j).

A mixture of propionaldehyde (2.15 g, 2.65 mL, 0.037 mol), dodecyl 3-oxobutanoate (10 g, 0.037 mol) and dodecyl 3-aminobutanoate (10 g, 0.037 mol) was stirred at reflux in ethanol (15 mL) for 8 h. After cooling the reaction mixture to 4 °C, the resulting precipitates were filtered, recrystallised twice from ethanol, and dried under vacuum giving compound **1j** (15.9 g, 76%) as a slightly yellow solid; Mp. 47–49 °C. ¹H-NMR (400 Hz, CDCl₃): δ 5.48 (s, 1H, NH), 4.18–4.02 (m, 4H, 2×COOCH₂(CH₂)₁₀CH₃), 3.93 (t, ³J_{H-H} = 5.5 Hz, 1H, CH(4)), 2.28 (s, 6H, 2×CH₃), 1.70–1.59 (m, 4H, 2×COOCH₂CH₂(CH₂)₈CH₂CH₃), 1.40–1.33 (m, 6H, 2×COOCH₂(CH₂)₉CH₂CH₃ and COOCH₂CH₃), 1.30–1.23 (m, 32H, 2×COOCH₂CH₂(CH₂)₈CH₂CH₃), 0.91–0.84 (m, 6H, 2×COOC₁₁H₂₂CH₃), 0.75 (t, *J* = 7.5 Hz, 3H, COOCH₂CH₃) ppm. ¹³C-NMR (101 Hz, CDCl₃): δ 168.4, 144.9, 103.0, 63.9, 34.2, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 28.9, 26.3, 22.8, 19.6, 14.3, 9.4 ppm. HRMS (TOF MS ES⁺): calculated [C₃₅H₆₂NO₄ + H – 2H] 660.4679; found 660.4678.

1.2. Monofluorination of 1,4-dihydropyridines 1a,e

Scheme S3. Monofluorination of 1,4-dihydropyridines **1a,e**.

General procedure: To a solution of Quinine (1.05 eq.) and Selectfluor® (1.05 eq.) in dry MeCN (3 mL) under an argon atmosphere 3Å MS were added. The reaction mixture was stirred for 1 hour followed by the addition of 1,4-dihydropyridine (0.05 mmol, 1.0 eq.). After being stirred at RT for additional 24 hours the reaction mixture was concentrated in vacuum, resuspended in diethyl ether, filtered and the filtrate was concentrated in vacuum. The remaining residue was purified via column chromatography (eluent: mixture of EtOAc/PE) giving:

Dimethyl (3',4')-3'-fluoro-6'-methyl-2'-methylene-1',2',3',4'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (1'a). Following the general procedure and using quinine (15 mg, 0.05 mmol), Selectfluor® (17 mg, 0.05 mmol) and 1,4-DHP **1a** (15 mg, 0.05 mmol), after purification with column chromatography (eluent: EtOAc/PE = 1/3), compound **1'a** (11 mg, 66%) was obtained as a pale yellow solid. ¹H-NMR (400 Hz, DMSO-*d*₆): δ 9.40 (br s, 1H, NH), 8.38 (dd, ³J_{H-H} = 4.9 Hz, ⁴J_{H-H} = 1.5 Hz, 1H, CH, Py), 8.21 (d, ⁴J_{H-H} = 1.9 Hz, 1H, CH, Py), 7.35 (dt, ³J_{H-H} = 7.8, ⁴J_{H-H} = 1.9 Hz, 1H, CH, Py), 7.26 (dd, ³J_{H-H} = 7.8 Hz, ⁴J_{H-H} = 4.9 Hz, 1H, CH, Py), 4.88–4.83 (m, 1H, =CH_AH_B), 4.49–4.43 (m, 1H, =CH_AH_B), 4.26 (d, ³J_{H-F} = 10.7 Hz, 1H, CH(4)), 3.55 (s, 3H, COOCH₃), 3.46 (s, 3H, COOCH₃), 2.36 (s, 3H, CH₃) ppm. ¹³C-NMR (101 Hz, DMSO-*d*₆): δ 166.8 (d, *J* = 25 Hz), 166.5, 149.4, 148.2, 148.1, 135.8 (d, *J* = 16 Hz), 135.4, 135.0 (d, *J* = 8 Hz), 123.3, 97.4 (d, *J* = 9 Hz), 95.3, 91.1 (d, *J* = 186 Hz), 52.5, 50.5, 45.2 (d, *J* = 29 Hz), 19.1 ppm. ¹⁹F-NMR (376 Hz, DMSO-*d*₆): δ -136.9 (m) ppm.

Diethyl (3,4)-3'-fluoro-6'-methyl-2'-methylene-1',2',3',4'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (1'e). Following the general procedure and using quinine (15 mg, 0.05 mmol), Selectfluor® (17 mg, 0.05 mmol) and 1,4-DHP **1e** (15 mg, 0.05 mmol), after purification with column chromatography (eluent: EtOAc/PE = 1/3), compound **1'e** (11 mg, 72%) was obtained as a pale yellow solid. ¹H-NMR (400 Hz, CDCl₃): δ 8.45 (dd, ³J_{H-H} = 4.9 Hz, ⁴J_{H-H} = 1.5 Hz, 1H, CH, Py), 8.37 (d, ⁴J_{H-H} = 1.9 Hz, 1H, CH, Py), 7.42 (dt, ³J_{H-H} = 7.9 Hz, ⁴J_{H-H} = 1.9 Hz, 1H, CH, Py), 7.18 (dd, ³J_{H-H} = 7.9 Hz, ⁴J_{H-H} = 4.9 Hz, 1H, CH, Py), 6.73 (br s, 1H, NH), 4.77–4.74 (m, 1H, =CH_AH_B), 4.59 (dd, ²J_{H-F} = 5.7 Hz, ⁴J_{H-F} = 2.0 Hz, 1H, =CH_AH_B), 4.40 (d, ³J_{H-F} = 11.8 Hz, 1H, CH(4)), 4.13–4.05 (m, 1H, COOCH₂CH₃), 4.04–3.95 (m, 3H, COOCH₂CH₃ un COOCH₂CH₃), 2.44 (s, 3H, CH₃), 1.14 (t, ³J_{H-H} = 7.1 Hz, 3H, COOCH₂CH₃), 1.05 (t, ³J_{H-H} = 7.1 Hz, 3H, COOCH₂CH₃) ppm. ¹³C-NMR (101 Hz, CDCl₃): δ 167.0 (d, *J* = 25 Hz), 166.8, 150.0, 148.3, 146.7, 136.2, 136.1 (d, *J* = 18 Hz), 135.6 (d, *J* = 8 Hz), 123.3, 98.1, 97.5 (d, *J* = 9 Hz), 91.1 (d, *J* = 188 Hz), 62.2, 59.7, 46.1 (d, *J* = 28 Hz), 20.4, 14.4, 13.9 ppm. ¹⁹F-NMR (376 Hz, CDCl₃): δ -138.0 (m) ppm.

Stability and transformation of 3-fluoro-2-methylene-1,2,3,4-tetrahydropyridine derivatives


The 3-fluoro-2-methylene-1,2,3,4-tetrahydropyridine-3,5-dicarboxylates **1'a,e**, obtained as products from equimolar reactions of 1,4-DHPs **1a,e** with *N*-fluoro quinine were found to be unstable. After one week of storage, these compounds were converted to the corresponding pyridines **Ox-1a,e** through the elimination of hydrogen fluoride. The structure of obtained diethyl 2',6'-dimethyl-[3,4'-bipyridine]-3',5'-dicarboxylate (**Ox-1e**) was confirmed by NMR spectra (Figure S21), ¹H-NMR data were in accordance with the literature.¹ Dimethyl 2',6'-dimethyl-[3,4'-bipyridine]-3',5'-dicarboxylate (**Ox-1a**) was confirmed by LC-MS data in analogy with compound **Ox-1e**. The synthesis of dimethyl 2',6'-dimethyl-[3,4'-bipyridine]-3',5'-dicarboxylate (**Ox-1a**) from the corresponding 1,4-DHP derivatives was previously reported.²

Dimethyl 2',6'-dimethyl-[3,4'-bipyridine]-3',5'-dicarboxylate (Ox-1a): ¹H-NMR (400 Hz, CDCl₃): δ 8.63 (dd, ³J_{H-H} = 4.9 Hz, ⁴J_{H-H} = 1.7 Hz, 1H, CH, Py), 8.49 (dd, ⁴J_{H-H} = 2.3 Hz, ⁴J_{H-H} = 1.0 Hz, 1H, CH, Py), 7.59 (ddd, ³J_{H-H} = 7.9 Hz, ⁴J_{H-H} = 2.3 Hz, ⁴J_{H-H} = 1.7 Hz, 1H, CH, Py), 7.33 (ddd, ³J_{H-H} = 7.9 Hz, ³J_{H-H} = 4.9 Hz, ⁴J_{H-H} = 1.0 Hz, 1H, CH, Py), 3.57 (s, 6H, 2×COOCH₃), 2.62 (s, 6H, 2×CH₃) ppm. ¹³C-NMR (101 Hz, CDCl₃): δ 168.0, 156.3, 149.7, 148.5, 135.6, 132.5, 126.9, 122.9, 77.4, 52.5, 23.3 ppm.

Diethyl 2',6'-dimethyl-[3,4'-bipyridine]-3',5'-dicarboxylate (Ox-1e): ¹H-NMR (400 Hz, CDCl₃): δ 8.61 (dt, ³J_{H-H} = 4.9 Hz, ⁴J_{H-H} = 1.5 Hz, 1H, CH, Py), 8.50 (dt, ⁴J_{H-H} = 2.4 Hz, ⁴J_{H-H} = 1.2 Hz, 1H, CH, Py), 7.58 (ddd, ³J_{H-H} = 7.8 Hz, ⁴J_{H-H} = 2.4 Hz, ⁴J_{H-H} = 1.5 Hz, 1H, CH, Py), 7.30 (ddd, ³J_{H-H} = 7.8 Hz, ³J_{H-H} = 4.9 Hz, ⁴J_{H-H} = 1.2 Hz, 1H, CH, Py), 4.05–3.98 (m, 4H, 2×COOCH₂CH₃), 2.60 (s, 6H, 2×CH₃), 0.96–0.90 (m, 6H, 2×COOCH₂CH₃) ppm. ¹³C-NMR (101 Hz, CDCl₃): δ 167.4, 156.1, 149.7, 148.7, 142.7, 135.8, 132.7, 127.0, 122.8, 61.7, 23.2, 13.8 ppm.

1.3. Heck reaction

Table S1. Studies of Heck reaction of 2-methylenetetrahydropyridine **2d** with iodobenzene.



Entry	Pd cat.	Solvent	Base	Ligand	T (°C)	Time (h)	Conversion ^a (%)
1	Pd(OAc) ₂	DMF	TEA	PPh ₃	90	18	0
2	Pd(dppf)Cl ₂	DMF	TEA	PPh ₃	90	18	0
3	Pd(OAc) ₂	MeCN	Ag ₂ CO ₃	PPh ₃	RT	18	0
4	Pd(OAc) ₂	MeCN	Ag ₂ CO ₃	PPh ₃	60	18	< 5
5	Pd(dppf)Cl ₂	MeCN	Ag ₂ CO ₃	-	60	18	0
6	Pd(PPh ₃) ₂ Cl ₂	MeCN	Ag ₂ CO ₃	-	60	18	< 5

^aBy LCMS data

General procedure: To a stirred solution of 2-methylenetetrahydropyridine **2d** (1.0 eq.) in a pressure tube at the selected temperature of the experiment under an argon atmosphere, iodobenzene (1.3 eq.), base (2.0 eq.), Pd catalyst (10 mol%), and ligand (20 mol%, if required) were added. The reaction mixture was stirred at the selected temperature for 18 hours, with progress monitored by LC-MS.

1.4. Bromination of compound 2d




Figure S1. Studies of bromination reaction the methylene group of 2-methylenetetrahydropyridine **2d** with NBS monitored via ^{19}F NMR spectroscopy to track intermediate formation and product conversion.


2d: $^{19}\text{F}\{^1\text{H}\}$ NMR (564 MHz, MeOD) δ -139.15 (d, J = 22 Hz), -141.50 (d, J = 22 Hz).

10: $^{19}\text{F}\{^1\text{H}\}$ NMR (564 MHz, MeOD) δ -132.83 (d, J = 7 Hz), -164.14 (br.s).

7b: $^{19}\text{F}\{^1\text{H}\}$ NMR (564 MHz, MeOD) δ -138.37 (d, J = 22 Hz), -140.14 (d, J = 22 Hz).

1.5. Optimisation of quaternisation reaction

Table S2. Screening for the optimal conditions of quaternisation of the pyridine moiety in dialkyl 3,5-difluoro-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylates **13b,c**.



Entry	Comp.	R	X	Additive	T (°C)	Time (days)	Conversion ^a (%)
1	14a	CH ₃	I	-	RT	1	99
2	14b	C ₆ H ₁₃	Br	-	50	3	9
3	14b	C ₆ H ₁₃	Br	KI	50	3	28
4	14b	C ₆ H ₁₃	Br	NaI	50	3	76
5	14c	C ₁₂ H ₂₅	Br	-	50	3	0
6	14c	C ₁₂ H ₂₅	Br	KI	50	3	15

^aBy LCMS data

General procedure: To a solution of 2-methylenetetrahydropyridine **13b** (1.0 eq.) in acetone (1 mL), the corresponding alkyl halide: MeI (5.0 eq.), hexyl bromide (3.0 eq.), or dodecyl bromide (3.0 eq.) was added. For

reactions with hexyl bromide or dodecyl bromide, potassium iodide (KI, 3.0 eq.) or sodium iodide (NaI, 3.0 eq.) was also added to the mixture. The reaction mixture was stirred at RT or heated to 50 °C, depending on the conditions, and the conversion was monitored by LC-MS.

1.6. Dynamic light scattering measurements

Table S3. DLS measurement results.

Entry	Comp.	After 1 day storage		After 4 days storage		After 7 days storage		After 32 days storage		Zeta potential ±SD (mV)
		D _{avg} ±SD (nm)	PDI±SD	D _{avg} ±SD (nm)	PDI±SD	D _{avg} ±SD (nm)	PDI±SD	D _{avg} ±SD (nm)	PDI±SD	
1	14a	61±2	0.17±0.01	65±2	0.25±0.02	62±1	0.23±0.01	61±1	0.23±0.01	21.2±0.5
2	14b	196±11	0.46±0.07	306±4	0.38±0.01	253±5	0.31±0.01	-	-	5.5±0.1
3	14c	117±1	0.26±0.01	108±1	0.17±0.01	111±1	0.17±0.01	115±3	0.19±0.01	40.9±1.2
4	15a	75±2	0.37±0.01	74±1	0.37±0.02	72±1	0.37±0.01	69±1	0.37±0.01	51.6±1.0
5	15b	199±3	0.56±0.01	202±2	0.54±0.01	183±1	0.47±0.01	160±3	0.44±0.01	46.4±1.2
6	15c	158±5	0.46±0.03	121±1	0.20±0.01	120±1	0.22±0.01	112±1	0.25±0.01	30.9±0.9

1.7. NMR spectra




Figure S2. ¹H-NMR spectrum of didodecyl 2',6'-dimethyl-1',4'-dihydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**1h**).




Figure S3. ¹³C-NMR spectrum of didodecyl 2',6'-dimethyl-1',4'-dihydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**1h**).




Figure S4. ¹H-NMR spectrum of didodecyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-pyridine-3,5-dicarboxylate (**1i**).




Figure S7. ¹³C-NMR spectrum of didodecyl 4-ethyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (**1j**).




Figure S8. ¹H-NMR spectrum of bis(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9-hexadecafluorononyl) 2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate (**1m**).




Figure S9. ^{13}C -NMR spectrum of bis(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononyl) 2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate (**1m**).






Figure S10. ^{19}F -NMR spectrum of bis(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorononyl) 2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate (**1m**).






Figure S13. ¹⁹F-NMR spectrum of dimethyl (3,4)-3'-fluoro-6'-methyl-2'-methylene-1',2',3',4'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**1'a**).




Figure S14. ¹H-NMR spectrum of diethyl (3,4)-3'-fluoro-6'-methyl-2'-methylene-1',2',3',4'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**1'e**).




Figure S15. ¹³C-NMR spectrum of diethyl (3,4)-3'-fluoro-6'-methyl-2'-methylene-1',2',3',4'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (1'e).




Figure S16. ¹⁹F-NMR spectrum of diethyl (3,4)-3'-fluoro-6'-methyl-2'-methylene-1',2',3',4'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (1'e).




Figure S17. 2D HSQC NMR spectrum of diethyl (3,4)-3'-fluoro-6'-methyl-2'-methylene-1',2',3',4'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**1'e**).




Figure S18. 2D HMBC NMR spectrum of diethyl (3,4)-3'-fluoro-6'-methyl-2'-methylene-1',2',3',4'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**1'e**).




Figure S19. ^1H -NMR spectrum of dimethyl 2',6'-dimethyl-[3,4'-bipyridine]-3',5'-dicarboxylate (**Ox-1a**).




Figure S20. ^{13}C -NMR spectrum of dimethyl 2',6'-dimethyl-[3,4'-bipyridine]-3',5'-dicarboxylate (**Ox-1a**).




Figure S21. ¹H-NMR spectrum of diethyl 2',6'-dimethyl-[3,4'-bipyridine]-3',5'-dicarboxylate (**Ox-1e**).




Figure S22. ¹³C-NMR spectrum of diethyl 2',6'-dimethyl-[3,4'-bipyridine]-3',5'-dicarboxylate (**Ox-1e**).




Figure S23. ^1H -NMR spectrum of dimethyl (3',4',5')-3',5'-difluoro-6'-methyl-2'-methylene-2',3',4',5'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**2a**).




Figure S24. ^{13}C -NMR spectrum of dimethyl (3',4',5')-3',5'-difluoro-6'-methyl-2'-methylene-2',3',4',5'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**2a**).




Figure S25. ¹⁹F-NMR spectrum of dimethyl (3',4',5')-3',5'-difluoro-6'-methyl-2'-methylene-2',3',4',5'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**2a**).




Figure S26. ¹H-NMR spectrum of dimethyl (3,4,5)-3,5-difluoro-4-(4-methoxyphenyl)-6-methyl-2-methylene-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2b**).




Figure S27. ¹³C-NMR spectrum of dimethyl (3,4,5)-3,5-difluoro-4-(4-methoxyphenyl)-6-methyl-2-methylene-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2b**).




Figure S28. ¹⁹F-NMR spectrum of dimethyl (3,4,5)-3,5-difluoro-4-(4-methoxyphenyl)-6-methyl-2-methylene-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2b**).




Figure S29. ^1H -NMR spectrum of dimethyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-(3,4,5-trimethoxyphenyl)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2c**)




Figure S30. ^{13}C -NMR spectrum of dimethyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-(3,4,5-trimethoxyphenyl)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2c**).




Figure S31. ^{19}F -NMR spectrum of dimethyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-(3,4,5-trimethoxyphenyl)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (2c).




Figure S32. ^1H -NMR spectrum of diethyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (2d).




Figure S33. ¹³C-NMR spectrum of diethyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2d**).






Figure S34. ¹⁹F-NMR spectrum of diethyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2d**).






Figure S37. ¹³C-NMR spectrum of diethyl (3',4',5')-3',5'-difluoro-6'-methyl-2'-methylene-2',3',4',5'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**2e**).






Figure S38. ¹⁹F-NMR spectrum of diethyl (3',4',5')-3',5'-difluoro-6'-methyl-2'-methylene-2',3',4',5'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**2e**).






Figure S41. ¹⁹F-NMR spectrum of diethyl (3,4,5)-4-(4-bromophenyl)-3,5-difluoro-6-methyl-2-methylene-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2f**).




Figure S42. ¹H-NMR spectrum of didodecyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2g**).




Figure S43. ^{13}C -NMR spectrum of didodecyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2g**).




Figure S44. ^{19}F -NMR spectrum of didodecyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2g**).




Figure S45. ¹H-NMR spectrum of didodecyl (3',4',5')-3',5'-difluoro-6'-methyl-2'-methylene-2',3',4',5'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**2h**).




Figure S46. ¹³C-NMR spectrum of didodecyl (3',4',5')-3',5'-difluoro-6'-methyl-2'-methylene-2',3',4',5'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**2h**).




Figure S47. ¹⁹F-NMR spectrum of Didodecyl (3',4',5')-3',5'-difluoro-6'-methyl-2'-methylene-2',3',4',5'-tetrahydro-[3,4'-bipyridine]-3',5'-dicarboxylate (**2h**).




Figure S48. ¹H-NMR spectrum of didodecyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-(3-nitrophenyl)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2i**).




Figure S49. ¹³C-NMR spectrum of didodecyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-(3-nitrophenyl)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2i**).




Figure S50. ¹⁹F-NMR spectrum of Didodecyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-(3-nitrophenyl)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2i**).




Figure S51. ¹H-NMR spectrum of didodecyl (3,4,5)-4-ethyl-3,5-difluoro-6-methyl-2-methylene-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2j**).




Figure S52. ¹³C-NMR spectrum of didodecyl (3,4,5)-4-ethyl-3,5-difluoro-6-methyl-2-methylene-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2j**).




Figure S53. ¹⁹F-NMR spectrum of didodecyl (3,4,5)-4-ethyl-3,5-difluoro-6-methyl-2-methylene-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2j**).




Figure S54. ¹H-NMR spectrum of didodecyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-(thiophen-3-yl)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2k**).




Figure S55. ¹³C-NMR spectrum of didodecyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-(thiophen-3-yl)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2k**).




Figure S56. ¹⁹F-NMR spectrum of didodecyl (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-(thiophen-3-yl)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2k**).




Figure S57. ¹H-NMR spectrum of bis(2,2,3,3,4,4,5,5-octafluoropentyl) (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2I**).








Figure S58. ¹³C-NMR spectrum of bis(2,2,3,3,4,4,5,5-octafluoropentyl) (3,4,5)-3,5-difluoro-6-methyl-2-methylene-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**2I**).








Figure S63. ¹H-NMR spectrum of diethyl (3,4,5,Z)-2-(chloromethylene)-3,5-difluoro-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**7a**).




Figure S64. ¹³C-NMR spectrum of diethyl (3,4,5,Z)-2-(chloromethylene)-3,5-difluoro-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**7a**).




Figure S67. ^{13}C -NMR spectrum of diethyl (3,4,5,Z)-2-(bromomethylene)-3,5-difluoro-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**7b**).






Figure S68. ^{19}F -NMR spectrum of diethyl (3,4,5,Z)-2-(bromomethylene)-3,5-difluoro-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**7b**).






Figure S71. ¹⁹F-NMR spectrum of didodecyl (3,4,5,Z)-2-(bromomethylene)-3,5-difluoro-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**7c**).




Figure S72. ¹H-NMR spectrum of bromination intermediate - diethyl 2-(bromomethyl)-3,5-difluoro-2-methoxy-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**10**). ¹H NMR (300 MHz, CDCl₃) δ 7.23 – 7.18 (m, 3H, Ph), 7.15 – 7.09 (m, 2H, Ph), 4.42 (dd, ³J_{H-F} = 32.4 Hz, ³J_{H-F} = 14.5 Hz, 1H, CH(4)), 4.30 – 4.03 (m, 4H, COOCH₂CH₃ and CH₂Br), 3.90 – 3.68 (m, 2H, COOCH₂CH₃), 3.44 (s, 3H, OCH₃), 1.64 – 1.62 (m, 3H, CH₃), 1.18 (t, J = 7.1 Hz, 3H, COOCH₂CH₃), 0.84 (t, J = 7.1 Hz, 3H, COOCH₂CH₃) ppm.




Figure S73. ¹H-NMR spectrum of diethyl (3,4,5)-2-((Z)-benzylidene)-3,5-difluoro-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**13a**).




Figure S74. ^{13}C -NMR spectrum of diethyl (3,4,5)-2-((Z)-benzylidene)-3,5-difluoro-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**13a**).








Figure S75. ^{19}F -NMR spectrum of diethyl (3,4,5)-2-((Z)-benzylidene)-3,5-difluoro-6-methyl-4-phenyl-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**13a**).









Figure S81. ^{19}F -NMR spectrum of didodecyl (3,4,5,Z)-3,5-difluoro-6-methyl-4-phenyl-2-(pyridin-4-ylmethylene)-2,3,4,5-tetrahydropyridine-3,5-dicarboxylate (**13c**).




Figure S82. ^1H -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(ethoxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-methylpyridin-1-ium iodide (**14a**).




Figure S83. ^{13}C -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(ethoxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-methylpyridin-1-ium iodide (**14a**).




Figure S84. ^{19}F -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(ethoxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-methylpyridin-1-ium iodide (**14a**).




Figure S85. ¹H-NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(ethoxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-hexylpyridin-1-ium iodide (**14b**).




Figure S86. ¹³C-NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(ethoxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-hexylpyridin-1-ium iodide (**14b**).




Figure S87. ¹⁹F-NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(ethoxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-hexylpyridin-1-ium iodide (**14b**).




Figure S88. ^1H -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(ethoxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-dodecylpyridin-1-ium iodide (**14c**).




Figure S89. ^{13}C -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(ethoxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-dodecylpyridin-1-ium iodide (**14c**).




Figure S90. ^{19}F -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(ethoxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-dodecylpyridin-1-ium iodide (**14c**).




Figure S91. ^1H -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(dodecyloxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-methylpyridin-1-ium iodide (**15a**).




Figure S92. ^{13}C -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(dodecyloxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-methylpyridin-1-ium iodide (15a).




Figure S93. ^{19}F -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(dodecyloxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-methylpyridin-1-ium iodide (15a).




Figure S94. ¹H-NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(dodecyloxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-hexylpyridin-1-ium iodide (**15b**).




Figure S95. ¹³C-NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(dodecyloxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-hexylpyridin-1-ium iodide (**15b**).





Figure S97. ^1H -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(dodecyloxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-dodecylpyridin-1-ium iodide (**15c**).




Figure S98. ^{13}C -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(dodecyloxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-dodecylpyridin-1-ium iodide (**15c**).




Figure S99. ^{19}F -NMR spectrum of 4-((Z)-((3,4,5)-3,5-bis(dodecyloxycarbonyl)-3,5-difluoro-6-methyl-4-phenyl-4,5-dihydropyridin-2(3H)-ylidene)methyl)-1-dodecylpyridin-1-ium iodide (**15c**).

1.8. Crystallization procedure, crystal data, data collection and structure refinement details

Breafly, compound **2d** or **13a** (4 mg) was dissolved in hexane (4 mL) under reflux in a glass vial. The vial was loosely capped with a septum and pierced by a needle to allow slow solvent evaporation under ambient conditions. After two weeks, colorless single crystals suitable for X-ray diffraction were obtained.

Table S4. Experimental details for compound **2d**, CCDC Deposition Number: 2395307.

Crystal data ³	
Chemical formula	$\text{C}_{19}\text{H}_{21}\text{F}_2\text{NO}_4$
M_r	365.37
Crystal system, space group	Monoclinic, $P2_1/c$
Temperature (K)	160
a, b, c (Å)	16.7661 (2), 6.89850 (9), 16.2957 (2)
β (°)	102.2959 (14)
V (Å ³)	1841.55 (4)
Z	4
Radiation type	Cu $K\alpha$
μ (mm ⁻¹)	0.89
Crystal size (mm)	$0.3 \times 0.22 \times 0.14$
Data collection	
Diffractometer	XtaLAB Synergy, Dualflex, HyPix
Absorption correction	Multi-scan <i>CrysAlis PRO</i> 1.171.40.71a (Rigaku Oxford Diffraction, 2020) Empirical absorption correction using spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm.
$T_{\min}, T_{\max}$	0.845, 1.000
No. of measured, independent and observed [$I > 2\sigma(I)$] reflections	17724, 3734, 3578
R_{int}	0.022
$(\sin \theta/\lambda)_{\max}$ (Å ⁻¹)	0.631
Refinement	
$R[F^2 > 2\sigma(F^2)], wR(F^2), S$	0.035, 0.100, 1.06
No. of reflections	3734
No. of parameters	239
H-atom treatment	H-atom parameters constrained
$\Delta\rho_{\max}, \Delta\rho_{\min}$ (e Å ⁻³)	0.38, -0.18

Computer programs: *CrysAlis PRO* 1.171.42.93a (Rigaku OD, 2023), SHELXT 2014/4 (Sheldrick, 2014), SHELXL2018/3

(Sheldrick, 2018).

Table S5. Experimental details for compound **13a**, CCDC Deposition Number: 2395308.

Crystal data ³	
Chemical formula	C ₂₅ H ₂₅ F ₂ NO ₄
<i>M</i> _r	441.46
Crystal system, space group	Monoclinic, <i>P</i> 2 ₁ / <i>c</i>
Temperature (K)	150
<i>a</i> , <i>b</i> , <i>c</i> (Å)	12.5465 (5), 8.4111 (4), 20.7394 (3)
β (°)	94.1132 (19)
<i>V</i> (Å ³)	2183.00 (14)
<i>Z</i>	4
Radiation type	Cu <i>K</i> α
μ (mm ⁻¹)	0.85
Crystal size (mm)	0.24 × 0.16 × 0.10
Data collection	
Diffractometer	XtaLAB Synergy, Dualflex, HyPix
Absorption correction	Multi-scan <i>CrysAlis PRO</i> 1.171.42.93a (Rigaku Oxford Diffraction, 2023) Empirical absorption correction using spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm.
<i>T</i> _{min} , <i>T</i> _{max}	0.787, 1.000
No. of measured, independent and observed [<i>I</i> > 2σ(<i>I</i>)] reflections	20862, 4331, 3903
<i>R</i> _{int}	0.031
(sin θ/λ) _{max} (Å ⁻¹)	0.630
Refinement	
<i>R</i> [<i>F</i> ² > 2σ(<i>F</i> ²)], <i>wR</i> (<i>F</i> ²), <i>S</i>	0.033, 0.089, 1.00
No. of reflections	4331
No. of parameters	292
H-atom treatment	H-atom parameters constrained
Δρ _{max} , Δρ _{min} (e Å ⁻³)	0.30, -0.19

Computer programs: *CrysAlis PRO* 1.171.42.93a (Rigaku OD, 2023), SHELXT 2014/4 (Sheldrick, 2014), *SHELXL2018/3* (Sheldrick, 2018).

References

- 1 D. Shahabi, M. A. Amrollahi and A. A. Jafari, *J. Iran. Chem. Soc.*, 2011, **8**, 1052–1057.
- 2 M. A. Zolfigol, A. G. Choghamarani, M. Shahamirian, M. Safaiee, I. Mohammadpoor-Baltork, S. Mallakpour and M.

- Abdollahi-Alibeik, *Tetrahedron Lett.*, 2005, **46**, 5581–5584.
- 3 S. P. Westrip, *J. Appl. Crystallogr.*, 2010, **43**, 920–925.